Pfizer Japan Spin-out RaQualia Looks To Find Its Niche
This article was originally published in PharmAsia News
Executive Summary
Although RaQualia narrowly avoided the brunt of recent economic crises, timing still matters when finding a licensor, CEO says.
You may also be interested in...
Pfizer Japan Spinout RaQualia Cuts Another Deal With Korea's CJ CheilJedang
SEOUL - In a follow-up to a memorandum of understanding signed in 2010, CJ CheilJedang Corp. signed an agreement with RaQualia Pharm Inc. for exclusive rights to develop, manufacture and commercialize RaQualia's 5-HT4 partial agonist (RQ-0010) in South Korea, China, Taiwan, India and Southeast Asia
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.